Latest Breaking News On - Eur heartj cardiovasc - Page 1 : comparemela.com

Cleerly ISCHEMIA Software Device Billable With AMA Category I CPT Code for Noninvasive Estimates of Fractional Flow Reserve

FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease

United statesComunidad autonoma de catalunaGonzalez quesadaJamesp earlsEuropean association of cardiovascular imagingDrug administrationLate breaking clinical researchAmerican medical associationChief medical officerAmerican collegeCardiology annual scientific meeting new orleansPrognostic assessmentBased algorithmCoronary ischemiaEuropean associationCardiovascular imaging

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

Cleerly, Inc., a digital healthcare company focused on AI-driven heart disease diagnosis, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online in the European Heart Journal Cardiovascular Imaging.

United statesComunidad autonoma de catalunaJamesp earlsJames earlsGonzalez quesadaUdo hoffmanSociety of cardiovascular computed tomographyEuropean heart journal cv imagRadiology at george washington universityLate breaking clinical researchAmerican society of cardiac imagingCleerly incFellows of the society cardiovascularEuropean association of cardiovascular imagingEuropean heart journal cardiovascularDiagnostic certainty

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyUnited kingdomUniversity of pennsylvaniaUnited arab emiratesComunidad autonoma de catalunaGreat britainClin cardiolMichael millerJ cardiovasc pharmacotherAmerican heart associationOral abstract at european society of cardiologyDrug administrationExchange commissionAmarin corporationEuropean union

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent

Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively.

United statesNew jerseyUnited kingdomUniversity of pennsylvaniaUnited arab emiratesComunidad autonoma de catalunaGreat britainClin cardiolMichael millerJ cardiovasc pharmacotherAmerican heart associationOral abstract at european society of cardiologyDrug administrationExchange commissionAmarin corporationEuropean union

Amarin Corporation plc: New REDUCE-IT Data Show VASCEPA/VAZKEPA (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis

United statesNew jerseyUnited kingdomUniversity of pennsylvaniaUnited arab emiratesComunidad autonoma de catalunaGreat britainClin cardiolColl cardiolMichael millerJ cardiovasc pharmacotherAmerican heart associationOral abstract at european society of cardiologyDrug administrationExchange commissionAmarin corporation